Exciting updates from day 3 at the #IMS2024 meeting in Rio! Key findings on NDMM and RRMM treatments included: ▪️ Talvey (talquetamab), a GPRC5D-directed bispecific antibody, showed high response rates when used in different combinations with RRMM patients who had received 1 or more prior lines of therapy. ▪️ Findings showed that treatment with Carvykti, when compared to the standard of care (either Darzalex or Velcade combined with Pomalyst and dexamethasone), reduced the risk of death by 45%. ▪️ MRD-negativity rate more than doubled by 12 months when Darazlex was combined with Revlimid (D-R) in maintenance therapy compared to Revlimid alone in NDMM patients. Read all this and more in our blog from Day 3: https://lnkd.in/ehYfxtV6
Multiple Myeloma Research Foundation - MMRF
Non-profit Organizations
Norwalk, Connecticut 14,867 followers
Accelerating a smarter, faster, cure for mutiple myeloma.
About us
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15 FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.
- Website
-
http://themmrf.org
External link for Multiple Myeloma Research Foundation - MMRF
- Industry
- Non-profit Organizations
- Company size
- 51-200 employees
- Headquarters
- Norwalk, Connecticut
- Type
- Nonprofit
- Founded
- 1998
Locations
-
Primary
383 Main Avenue
5th Floor
Norwalk, Connecticut 06851, US
Employees at Multiple Myeloma Research Foundation - MMRF
-
Pam Lewis
Leader in Fundraising, Patient Advocacy and Programming. Catalyst and Pied Piper.
-
Christopher Williams
-
Adriana Davis
Producer/Editor/Voice-Over Artist, Director
-
Lori Tauber Marcus
Experienced Board Director, Chair, Compensation Committee, Nominating Governance Committee, Audit Committee, Board Development Committee, Public…
Updates
-
The MMRF CoMMpass study was the most groundbreaking research effort of the last decade and taught us so much about #myeloma. Hear MMRF partner and CoMMpass PI @TGen's Jonathan Keats on a recent podcast discussing the enduring impact of CoMMpass. The MMRF will continue to ensure its breakthrough initiatives help the entire field achieve cures.
In our most recent episode of TGen Talks, Jonathan Keats Ph.D., Assistant Professor of Integrated Cancer Genomics Division, shares about the CoMMpass Study in partnership with the Multiple Myeloma Research Foundation - MMRF . Keats discusses the decade-long project and the impact of its results, along with highlighting the urgent need for tailored therapies and innovative clinical trials. Listen at 🎙️ https://bit.ly/3Z5yeqV
-
Exciting updates from day 2 at the #IMS2024 meeting in Rio! Key findings on NDMM and RRMM treatments included: ▪️ Darzalex Velcade/Revlimid/dexamethasone shows 95% of NDMM patients, ages 65 , living disease-free 4 years after treatment compared to 65% who received VRd ▪️ Iberdomide Darzalex/dexamethasone was highly effective and had a manageable safety profile for patients deemed ineligible for transplant ages 65 ▪️ Carvykti shows high levels of response rates among patients who received prior BCMA therapy or bispecific antibodies Read all this and more in our blog from Day 2: https://ow.ly/AZ8Q50TxE2X
IMS 2024 Myeloma Oral Sessions Day 2 - MMRF
https://themmrf.org
-
MMRF Chief Mission Officer Anne Quinn Young is presenting a poster on the positive impact our education programs have on #myeloma patients. We arm patients and their families with the tools and resources they need to improve their care and extend their lives. #IMS2024
-
No matter your disease state, we offer a variety of resources to support you along your myeloma journey, including the MMRF Patient Toolkit and Fast Facts in Myeloma. To gain a better understanding of #myeloma, download these booklets and one-pagers: https://ow.ly/xGkk50Tsbjs #BloodCancerAwarenessMonth
-
Congratulations to longtime leader of the Multiple Myeloma Research Consortium and MMRF CoMMpass PI, Dr. Sagar Lonial on being this year’s Bart Barlogie Clinical Investigator Awardee! This award recognizes outstanding myeloma research. As a leading expert in the field of #myeloma, this recognition is well deserved. We are grateful to have Dr. Lonial as a partner in our mission to accelerate a cure for each and every patient. #IMS2024
-
🔬Exciting news from #IMS2024! MMRF Senior Scientist Dr. Chaitanya "Chuck" Acharya is presenting a poster on the potential of immune profiling of blood as a surrogate for bone marrow sampling. This innovative approach could transform patient care by making diagnostics less invasive.
-
Exciting updates from the #IMS2024 meeting in Rio! Findings on NDMM treatments included: ▪️ A maintenance regimen of Darzalex plus Revlimid shows over 90% of patients with standard risk have no disease progression after more than 4.5 years ▪️ High-risk patients who received Sarclisa, Kyprolis, Revlimid, and dexamethasone show survival rates exceeding 70% at 4 years and 60% at 6 years ▪️ Blenrep was safe and effective with VRd as first-line treatment for NDMM patients eligible for an ASCT Read all this and more in our blog from Day 1: https://ow.ly/BAjG50TwFOQ
IMS 2024 Myeloma Oral Sessions Day 1 - MMRF
https://themmrf.org
-
Don’t forget to join us in Detroit TOMORROW at 9:00 am ET! Spend a day with us and learn about the impact #myeloma has in the Black community. Register to attend our Multiple Myeloma Community Connect event in partnership with Acclinate: https://lnkd.in/ervQFyNc
-
The Myeloma Investment Fund® (MIF®) is the first investment fund in myeloma. Investing through this fund enables us to provide financial and strategic support to advance a robust pipeline of new myeloma therapies and improve the probability of their success for patients. Learn about the MIF: https://ow.ly/N6Rp50Tr2sr